CAMBRIDGE, MASSACHUSETTS — An international community of biomedical and healthcare innovation leaders gathered at MIT on December 12 and 13 for the second Design Lab for LEAPS (Learning Ecosystems Accelerator … Read More
Model Contracts for Innovative Oncology Therapies
When there is substantial uncertainty about a new product’s expected value, stakeholders may have strong reasons to consider performance-based contracts. One of the hardest tasks in crafting such contracts is … Read More
NPR: “A Search For New Ways To Pay For Drugs That Cost A Mint”
Installment plans and refunds for treatments that don’t work are two options getting more attention as ultra-expensive therapies become more common. The financial strains will only grow. Read and hear … Read More
Leaping Together Toward Sustainable, Patient‐Centered Innovation: The Value of a Multistakeholder Safe Haven for Accelerating System Change
Clinical Pharmacology & Therapeutics, November 2, 2018Gigi Hirsch Successfully delivering on the promise of emerging science in a world of value-driven healthcare requires that we fundamentally reengineer biomedical innovation processes … Read More
Alternative State-Level Financing for Hepatitis C Treatment—The “Netflix Model”
JAMA, October 29, 2018Mark R. Trusheim, William M. Cassidy, and Peter B. Bach Drug prices in the United States remain the highest in the world.1 New payment approaches are needed, … Read More
Role of COE networks in curative cellular oncology therapies
COE networks currently play an important role in the delivery of care for specialized service lines, including but not limited to solid organ transplantation (SOT), hematopoietic cell transplantation (HCT) and … Read More
FasterCures joins NEWDIGS Initiative at MIT as a Strategic Partner
Collaboration to drive innovation across healthcare ecosystem CAMBRIDGE, MA, 21 SEPTEMBER 2018–FasterCures, a center of the Milken Institute devoted to saving lives by speeding up and improving the medical research … Read More
Improving Management of Gene and Cell Therapies: The Orphan Reinsurer and Benefit Manager (ORBM)
D. Han; D.S. Mytelka; G.L. Warren; M. Ciarametaro; M. Trusheim. PharmaExec.com, 2018 After decades of anticipation, 2017 saw the approval of the first of a new generation of durable and … Read More
Improving Management of Gene and Cell Therapies
Pharmaceutical Executive, September 10, 2018Michael Ciarametaro, Mark Trusheim, Daniel S. Mytelka, Gregory L. Warren, and Donald Han After decades of anticipation, 2017 saw the approval of the first of a … Read More
FoCUS Research Team interviewed for article on Innovating Payment Models
The leads of the FoCUS Research Teams, Strategic Director Mark Trusheim, Research Advisor Casey Quinn, Director of Simulation & Policy Research Daniel Mytelka, and Director of Drug Development Pipeline Research … Read More